BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 15827196)

  • 1. Effect of antiviral treatment with entecavir on age- and dose-related outcomes of duck hepatitis B virus infection.
    Foster WK; Miller DS; Scougall CA; Kotlarski I; Colonno RJ; Jilbert AR
    J Virol; 2005 May; 79(9):5819-32. PubMed ID: 15827196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiviral therapy with entecavir combined with post-exposure "prime-boost" vaccination eliminates duck hepatitis B virus-infected hepatocytes and prevents the development of persistent infection.
    Miller DS; Boyle D; Feng F; Reaiche GY; Kotlarski I; Colonno R; Jilbert AR
    Virology; 2008 Apr; 373(2):329-41. PubMed ID: 18206204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Entecavir therapy combined with DNA vaccination for persistent duck hepatitis B virus infection.
    Foster WK; Miller DS; Marion PL; Colonno RJ; Kotlarski I; Jilbert AR
    Antimicrob Agents Chemother; 2003 Aug; 47(8):2624-35. PubMed ID: 12878529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The persistence in the liver of residual duck hepatitis B virus covalently closed circular DNA is not dependent upon new viral DNA synthesis.
    Reaiche GY; Le Mire MF; Mason WS; Jilbert AR
    Virology; 2010 Oct; 406(2):286-92. PubMed ID: 20705309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Establishment of an in vivo model for duck hepatitis B virus infection using Hubei duckling].
    Hu Q; Fang Y; Zhang ZM; Zhang XY; Zhang ZH; Yang DL
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Apr; 22(2):113-5. PubMed ID: 18574531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The development of persistent duck hepatitis B virus infection can be prevented using antiviral therapy combined with DNA or recombinant fowlpoxvirus vaccines.
    Feng F; Teoh CQ; Qiao Q; Boyle D; Jilbert AR
    Vaccine; 2010 Oct; 28(46):7436-43. PubMed ID: 20833122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination of ducks with a whole-cell vaccine expressing duck hepatitis B virus core antigen elicits antiviral immune responses that enable rapid resolution of de novo infection.
    Miller DS; Halpern M; Kotlarski I; Jilbert AR
    Virology; 2006 May; 348(2):297-308. PubMed ID: 16469347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiviral effects of PNA in duck hepatitis B virus infection model.
    Chen ZY; Cheng AC; Wang MS; Xu DW; Zeng W; Li Z
    Acta Pharmacol Sin; 2007 Oct; 28(10):1652-8. PubMed ID: 17883953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nucleic acid polymer REP 2139 and nucleos(T)ide analogues act synergistically against chronic hepadnaviral infection in vivo in Pekin ducks.
    Quinet J; Jamard C; Burtin M; Lemasson M; Guerret S; Sureau C; Vaillant A; Cova L
    Hepatology; 2018 Jun; 67(6):2127-2140. PubMed ID: 29251788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of age- and dose-related outcomes of duck hepatitis B virus infection.
    Jilbert AR; Botten JA; Miller DS; Bertram EM; Hall PM; Kotlarski J; Burrell CJ
    Virology; 1998 May; 244(2):273-82. PubMed ID: 9601498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duck HBV DNA copy numbers in isolated hepatocyte nuclei vary dramatically and decline during entecavir therapy.
    Shen G; Fu X; Zhou B; Yin J; Zhong C; Chen J; Hou J
    Antivir Ther; 2013; 18(8):987-96. PubMed ID: 23765241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetics of duck hepatitis B virus infection following low dose virus inoculation: one virus DNA genome is infectious in neonatal ducks.
    Jilbert AR; Miller DS; Scougall CA; Turnbull H; Burrell CJ
    Virology; 1996 Dec; 226(2):338-45. PubMed ID: 8955053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Covalently closed circular DNA is the predominant form of duck hepatitis B virus DNA that persists following transient infection.
    Le Mire MF; Miller DS; Foster WK; Burrell CJ; Jilbert AR
    J Virol; 2005 Oct; 79(19):12242-52. PubMed ID: 16160150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Inhibitory effect of trisodium phosphonoformate (PFA) on duck hepatitis B virus (DHBV) DNA in vivo].
    Chen X; Chen H
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1997 Sep; 11(3):277-81. PubMed ID: 15617348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA vaccines expressing the duck hepatitis B virus surface proteins lead to reduced numbers of infected hepatocytes and protect ducks against the development of chronic infection in a virus dose-dependent manner.
    Miller DS; Kotlarski I; Jilbert AR
    Virology; 2006 Jul; 351(1):159-69. PubMed ID: 16624364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic Antiviral Effect of the Nucleic Acid Polymer REP 2055 against Persistent Duck Hepatitis B Virus Infection.
    Noordeen F; Scougall CA; Grosse A; Qiao Q; Ajilian BB; Reaiche-Miller G; Finnie J; Werner M; Broering R; Schlaak JF; Vaillant A; Jilbert AR
    PLoS One; 2015; 10(11):e0140909. PubMed ID: 26560490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo and in vitro anti-hepatitis B virus activity of total phenolics from Oenanthe javanica.
    Han YQ; Huang ZM; Yang XB; Liu HZ; Wu GX
    J Ethnopharmacol; 2008 Jun; 118(1):148-53. PubMed ID: 18495393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Anti-virus effect of hepatocyte stimulating substance (HSS) on duck hepatitis B virus in vivo].
    Chen G; Chen J; Liu D; Zhang X; Zhu C; Li Y; Wang L; Yang Y; Cai G; Han F
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1997 Dec; 11(4):329-32. PubMed ID: 15617240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the antiviral effects of 2' carbodeoxyguanosine in ducks chronically infected with duck hepatitis B virus.
    Mason WS; Cullen J; Saputelli J; Wu TT; Liu C; London WT; Lustbader E; Schaffer P; O'Connell AP; Fourel I
    Hepatology; 1994 Feb; 19(2):398-411. PubMed ID: 8294097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo infectivity of liver extracts after resolution of hepadnaviral infection following therapy associating DNA vaccine and cytokine genes.
    Saade F; Buronfosse T; Guerret S; Pradat P; Chevallier M; Zoulim F; Jamard C; Cova L
    J Viral Hepat; 2013 Apr; 20(4):e56-65. PubMed ID: 23490390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.